Next Science (NXS) Stock Overview
Engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NXS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Next Science Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.15 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.056 |
| Beta | 1.13 |
| 1 Month Change | 0% |
| 3 Month Change | 7.14% |
| 1 Year Change | 7.14% |
| 3 Year Change | -79.73% |
| 5 Year Change | -87.01% |
| Change since IPO | -88.89% |
Recent News & Updates
Even With A 125% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely
Jul 17
Next Science Limited (ASX:NXS) Might Not Be As Mispriced As It Looks After Plunging 29%
May 28Recent updates
Even With A 125% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely
Jul 17Next Science Limited (ASX:NXS) Might Not Be As Mispriced As It Looks After Plunging 29%
May 28
Cost Restructuring And XPERIENCE Trials Will Strengthen Future Position
Transitioning to a variable cost structure decreased cash burn, likely improving net margins and EBITDA as growth continues.Would Next Science (ASX:NXS) Be Better Off With Less Debt?
Mar 17Even With A 26% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely
Jan 22Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 36% Cheaper
Oct 22Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 29% Bounce
Jul 26It's Down 32% But Next Science Limited (ASX:NXS) Could Be Riskier Than It Looks
Jun 08Will Next Science (ASX:NXS) Spend Its Cash Wisely?
Apr 16Further Upside For Next Science Limited (ASX:NXS) Shares Could Introduce Price Risks After 26% Bounce
Mar 06Potential Upside For Next Science Limited (ASX:NXS) Not Without Risk
Dec 26Next Science Limited (ASX:NXS) Analysts Just Trimmed Their Revenue Forecasts By 10%
Oct 26Take Care Before Jumping Onto Next Science Limited (ASX:NXS) Even Though It's 26% Cheaper
May 13The Next Science Limited (ASX:NXS) Analysts Have Been Trimming Their Sales Forecasts
Feb 03Here's Why We're Not Too Worried About Next Science's (ASX:NXS) Cash Burn Situation
Jan 25Next Science Limited (ASX:NXS) Is Expected To Breakeven In The Near Future
Mar 07Here's Why We're Watching Next Science's (ASX:NXS) Cash Burn Situation
Feb 14
Did Next Science Limited (ASX:NXS) Insiders Buy Up More Shares?
Jan 18Do Institutions Own Next Science Limited (ASX:NXS) Shares?
Dec 20Shareholder Returns
| NXS | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -3.2% | 1.7% | -1.0% |
| 1Y | 7.1% | 4.5% | 9.2% |
Return vs Industry: NXS exceeded the Australian Medical Equipment industry which returned 4.5% over the past year.
Return vs Market: NXS underperformed the Australian Market which returned 9.2% over the past year.
Price Volatility
| NXS volatility | |
|---|---|
| NXS Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 11.4% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 20.2% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: NXS has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NXS's weekly volatility has decreased from 14% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | I.V. Hall | www.nextscience.com |
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Next Science Limited Fundamentals Summary
| NXS fundamental statistics | |
|---|---|
| Market cap | AU$43.89m |
| Earnings (TTM) | -AU$14.32m |
| Revenue (TTM) | AU$33.51m |
Is NXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXS income statement (TTM) | |
|---|---|
| Revenue | US$22.07m |
| Cost of Revenue | US$3.87m |
| Gross Profit | US$18.20m |
| Other Expenses | US$27.63m |
| Earnings | -US$9.43m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.032 |
| Gross Margin | 82.48% |
| Net Profit Margin | -42.74% |
| Debt/Equity Ratio | -849.6% |
How did NXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/29 15:44 |
| End of Day Share Price | 2025/10/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Next Science Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.